UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): June 13, 2025
BioRestorative Therapies, Inc.
(Exact name of registrant as specified in its charter)
|
Nevada
|
|
001-37603
|
|
30-1341024
|
|
(State or other jurisdiction
of incorporation)
|
|
(Commission
File Number)
|
|
(IRS Employer
Identification No.)
|
|
40 Marcus Drive
Melville, New York
|
|
11747
|
|
(Address of principal executive offices)
|
|
(Zip code)
|
Registrant's telephone number, including area code (631) 760-8100
Not Applicable
(Former Name or Former Address, if Changed Since Last Report)
Securities registered pursuant to Section 12(b) of the Securities Exchange Act of 1934:
|
Title of each class
|
Trading Symbol(s)
|
Name of each exchange on which registered
|
BRTX
|
BRTX
|
NASDAQ Capital Market
|
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following
provisions (see General Instruction A.2. below):
☐ Written communications pursuant to Rule 425 under the Securities
Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act
(17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under
the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under
the Exchange Act (17 CFR 240.13e-4(c))
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act
of 1934 (§240.12b-2 of this chapter):
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards
provided pursuant to Section 13(a) of the Exchange Act. ☐
|
Item 7.01
|
Regulation FD Disclosure.
|
On June 13, 2025, BioRestorative Therapies, Inc. (the “Company”) issued a press release (the “Press Release”)
announcing that Francisco Silva, Vice President of Research and Development, presented new preliminary, blinded clinical data from approximately 30 patients enrolled in its ongoing Phase 2 trial of BRTX-100 for the treatment of chronic lumbar disc
disease (“cLDD”) at the prestigious International Society for Stem Cell Research (“ISSCR”) 2025 Annual Meeting, taking place June 11-14, 2025 in Hong Kong. Mr. Silva’s presentation was entitled Stem Cell Therapy for Chronic Lumbar Disc Disease: Phase
2 Clinical Safety and Feasibility Data of Intradiscal Injections of Hypoxic Cultured Mesenchymal Stem Cells. A copy of the Press Release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.
At the ISSCR Annual Meeting, certain presentation materials (the “Presentation Materials”) were be utilized by Mr.
Silva. The Company intends to use the Presentation Materials from time to time on and after the date of this Current Report on Form 8-K in presentations about the Company’s business. As indicated above, the Company used the Presentation Materials
at the ISSCR Annual Meeting on June 13, 2025 and may use the Presentation Materials, possibly with modification, in other presentations to current and potential investors, lenders, creditors, insurers, vendors, customers, employees and others with an
interest in the Company and its business.
The information contained in the Presentation Materials is summary information that should be considered in the
context of the Company’s filings with the Securities and Exchange Commission and other public announcements that the Company may make by press release or otherwise from time to time. The Presentation Materials speak as of the date of this Current
Report on Form 8-K. While the Company may elect to update the Presentation Materials in the future or reflect events and circumstances occurring or existing after the date of this Current Report on Form 8-K, the Company specifically disclaims any
obligation to do so. The Presentation Materials are furnished as Exhibit 99.2 to this Current Report on Form 8-K and are incorporated herein by reference. The Presentation Materials will also be posted on the Company’s website, www.biorestorative.com, under “Scientific Publications” in the Product Candidate section, for 90 days.
The information referenced under this Item 7.01 (including Exhibits 99.1 and 99.2 referenced in Item 9.01 below) of
this Current Report on Form 8-K is being “furnished” under “Item 7.01. Regulation FD Disclosure” and, as such, shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject
to the liabilities of that section. The information set forth in this Current Report on Form 8-K (including Exhibits 99.1 and 99.2 referenced in Item 9.01 below) shall not be incorporated by reference into any registration statement, report or other
document filed by the Company pursuant to the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing.
|
Item 9.01
|
Financial Statements and Exhibits.
|
(d) Exhibits.
|
Number
|
Description
|
| |
|
|
99.1
|
|
| |
|
|
99.2
|
|
| |
|
|
104
|
Cover Page Interactive Data File (embedded within the Inline XBRL document)
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
| |
BIORESTORATIVE THERAPIES, INC.
|
|
| |
|
|
|
|
Dated: June 13, 2025
|
By:
|
/s/ Robert Kristal
|
|
| |
|
Robert Kristal
|
|
| |
|
Chief Financial Officer
|
|
| |
|
|
|